Nanobiotix (NANO) | Stock Overview & Key Data
Nanobiotix | Mid-cap | Healthcare
Nanobiotix | Mid-cap | Healthcare
Nanobiotix Performance Comparison
Stock Range
Today's Range
Low: €8.09
High: €8.89
on August 22, 2025
52 Week Range
Low: €2.62
High: €8.89
on April 7, 2025
on August 22, 2025
All-Time High: €33.12 on February 10, 2014
Explore how other French stocks compare to their 52-week ranges: View FR Market 52-Week Insights
Key Statistics
Market Cap
€360.4M
EPS
-1.44
P/E Ratio (TTM)
-5.10
Forward P/E
-7.09
P/B Ratio
N/A
PEG Ratio
-7.09
Div. Yield
N/A
ROE
103.70%
Beta
1.500
Debt to Equity
-0.77
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
271.42%
Profit Margin
0.00%
Returns and Earnings
Return on Assets (TTM)
-52.89%
Return on Equity (TTM)
103.70%
EBITDA
€-67.7M
Net Income (TTM)
€-68.1M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€-0.15
Quarterly Revenue Growth (YoY)
N/A
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Nanobiotix NANO | 360.37M Mid-cap | 22.27% | 90.14% | 148.20% | 130.28% | 170.03% | 76.01% | 99.28% | 19.45% |
| Abivax SA ABVX | 5.00B Large-cap | 10.83% | 647.19% | 1,173.95% | 807.23% | 813.46% | 539.42% | 705.08% | 258.30% |
| Valneva SE VLA | 857.12M Mid-cap | 11.79% | 84.64% | 72.38% | 32.88% | 113.42% | 42.90% | -46.70% | -6.45% |
| Medincell S.A MEDCL | 584.81M Mid-cap | 9.48% | 13.27% | 14.49% | 32.43% | 2.68% | -0.50% | 273.65% | 143.38% |
| Inventiva S.A IVA | 536.08M Mid-cap | 10.83% | 43.01% | 39.93% | 50.78% | 84.36% | 71.37% | -15.43% | -61.86% |
| BNP Paribas Easy BLUE | 463.10M Mid-cap | 0.06% | -0.51% | -2.12% | -4.61% | -4.09% | -3.20% | 1.88% | 51.49% |
Ownership & Short Interest
Insider Ownership
15.33%
Institutional Ownership
27.66%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
195K
Average 90-Day Volume
191K
Nanobiotix Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Nanobiotix would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is NANO's 52-week high and low?
- In the last 52 weeks, Nanobiotix reached a high of €8.89 (on August 22, 2025) and a low of €2.62 (on April 7, 2025).
- What is the market cap and P/E ratio for NANO?
- Curious about Nanobiotix's size and valuation? Its market capitalization stands at 360.37M. When it comes to valuation, the P/E ratio (trailing twelve months) is -5.10, and the forward P/E (looking ahead) is -7.09.
- Does NANO pay dividends? If so, what's the yield?
- As for dividends, Nanobiotix isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Nanobiotix's main competitors or similar companies to consider before investing?
When looking at Nanobiotix, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Abivax SA
ABVX5.00B Healthcare Biotechnology 539.42% 705.08% Valneva SE
VLA857.12M Healthcare Biotechnology 42.90% -46.70% Medincell S.A
MEDCL584.81M Healthcare Biotechnology -0.50% 273.65% Inventiva S.A
IVA536.08M Healthcare Biotechnology 71.37% -15.43% BNP Paribas Easy
BLUE463.10M Healthcare Biotechnology -3.20% 1.88% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Nanobiotix? (e.g., ROE, Debt/Equity)
- To get a sense of Nanobiotix's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 103.70%, the Debt to Equity ratio from the most recent quarter is -0.77, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for NANO?
- Looking at Nanobiotix's growth, its revenue over the trailing twelve months (TTM) was €-7M. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
- How much of NANO stock is held by insiders and institutions?
- Wondering who owns Nanobiotix stock? Company insiders (like executives and directors) hold about 15.33% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 27.66%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.